Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single pill beat two for diabetes control?

NCT ID NCT07057479

Disease control Sponsor: Eurofarma Laboratorios S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if a single pill combining two diabetes medications works better than taking them separately for people with type 2 diabetes already on metformin. The goal was to improve blood sugar control and reduce side effects like weight gain and swelling. However, the study was withdrawn before enrolling any participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent form * Age ≥18 years * Diagnosis of type 2 diabetes (T2DM) * HbA1c 7.5-10% while on stable metformin monotherapy (≥1000 mg/day) for ≥12 weeks * ≥80% adherence to run-in medication Exclusion Criteria: * Type 1 diabetes or other specific diabetes types (e.g., monogenic, pancreatic, or drug-induced) * Severe hyperglycemia (≥270 mg/dL) or diabetic ketoacidosis in past 12 weeks * Hypersensitivity to study drugs or excipients * Pregnancy, lactation, or planning pregnancy * Severe diabetic complications (proliferative retinopathy, severe neuropathy) * Major cardiovascular events in past 12 weeks (e.g., myocardial infarction, heart failure NYHA III/IV) * Uncontrolled hypertension (SBP \>180 mmHg or DBP \>110 mmHg) * Moderate/severe renal impairment (eGFR \<45 mL/min/1.73m²) * Liver disease (cirrhosis, active hepatitis) * History of malignancy (except treated skin cancers) in past 5 years * Use of non-metformin antidiabetics or weight-loss drugs in past 12 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diabetes Complications Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Eurofarma Laboratórios S.A

    Itapevi, São Paulo, 06696-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.